Background and Research environment :
The Luxembourg Institute of Health is offering a postdoctoral position within the Department of Infection and Immunity (group of Immuno-Pharmacology and Interactomics) in the area of cancer cell signalling to carry out a multidisciplinary research project on the involvement of chemokine receptors in glioblastoma.
Tumour growth and dissemination are among the most important aspects in cancer biology. Chemokines are a superfamily of chemo-attractant cytokines playing critical roles in these processes.
The biological effects of chemokines are mediated through seven-transmembrane receptors coupled to G proteins (GPCRs). Recently, different chemokine receptors and chemokines, notably atypical chemokine receptors (ACKRs) have been proposed to play a crucial role in glioblastoma, an aggressive malignant brain tumour.
The group of Immuno-Pharmacology and Interactomics investigates the fundamental and clinical implications of chemokine receptors in human biology and immuno-oncology-related processes and inflammatory diseases.
The Department of Infection and Immunity located at the House of BioHealth is a basic clinical-translational research entity aiming at understanding the complex mechanisms of infectious and inflammatory processes to enable new ways to diagnose, prevent and cure human diseases.
Building on a highly interdisciplinary research environment, its strategy bridges experimental discovery and validation with clinical application and technology development to address major unsolved medical needs in the areas of immune-mediated inflammation, cancer and infectious diseases.
The researchers of DII have access to state-of-the-art core facilities including cell culture labs, SPF animal house, confocal microscopy, interactomics, proteomics, genomics, flow cytometry (CyTOF, imaging flow cytometry,.
This project will investigate chemokine receptor functions, signalling and modulation in the context of glioblastoma biology.
The research efforts will be directed toward four convergent approaches :
Chevigné et al. Cancers 2021.
Sjoberg et al. Adv. Cancer Res. 2020 Meyrath et al. Nature Communications 2020. Reynders et al. Cells 2019 Sjoberg et al.
Clin Cancer Res. 2019. Willems et al. Oncogene 2019.
The successful candidate will join a highly dynamic research environment and get access to several core facilities and relevant state-of-the-art technologies.
S / he will benefit from an active seminar program and opportunities for conference attendance as well as collaborations with other research organizations and international partners.
Dr. Andy Chevigné, PhD
29 Rue Henri Koch